Statements (43)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
opioid analgesic
|
| gptkbp:activeDuring |
oxymorphone
|
| gptkbp:brand |
gptkb:Opana
|
| gptkbp:chemicalFormula |
C17H19NO4
|
| gptkbp:contraindication |
severe asthma
intestinal obstruction hypersensitivity to oxymorphone |
| gptkbp:date |
2006-04-04
|
| gptkbp:drugInterdiction |
gptkb:MAO_inhibitors
high CNS depressants |
| gptkbp:formFactor |
tablet
|
| gptkbp:gestationPeriod |
C
|
| https://www.w3.org/2000/01/rdf-schema#label |
Opana IR
|
| gptkbp:isA |
0A0D1F1D1D
|
| gptkbp:isATypeOf |
665-66-7
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Endo_Pharmaceuticals
|
| gptkbp:market |
2017
|
| gptkbp:notableFeature |
Opana ER
oxymorphone hydrochloride |
| gptkbp:numberOfStudents |
7-9 hours
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:operates_in |
N02AA06
|
| gptkbp:origin |
(5α)-17-((1-oxopropan-2-yl)oxy)-3-hydroxy-4,5-epoxy-6-morphinane-7,8-diol
|
| gptkbp:reform |
2012-01-01
abuse deterrent |
| gptkbp:route |
oral
|
| gptkbp:sideEffect |
dizziness
nausea constipation sedation respiratory depression |
| gptkbp:skills |
10 mg
5 mg 20 mg 40 mg |
| gptkbp:symptoms |
anxiety
muscle pain nausea insomnia sweating |
| gptkbp:usedFor |
pain management
|